Table 2.
Hepatitis C Treatment Parameters
| Parameters | Base Case | Low | High | Distribution | Source |
|---|---|---|---|---|---|
| Treatment Efficacy | |||||
| Sofosbuvir/Interferon/RBV | 0.92 | 0.69 | 1.00 | Beta | (11, 56) |
| Sofosbuvir/Interferon/RBV (F4) | 0.80 | 0.60 | 1.00 | Beta | (11) |
| Sofosbuvir/Simeprevir | 0.95 | 0.71 | 1.00 | Beta | (12) |
| Sofosbuvir/Simeprevir (F4) | 0.94 | 0.71 | 1.00 | Beta | (12) |
| SOF/LDV (8 weeks) | 0.94 | 0.71 | 1.00 | Beta | (19) |
| SOF/LDV (12 weeks) | 0.96 | 0.72 | 1.00 | Beta | (18, 19) |
| SOF/LDV (F4) | 0.97 | 0.73 | 1.00 | Beta | (18) |
| 3D/RBV Genotype 1a | 0.96 | 0.72 | 1.00 | Beta | (15, 16) |
| 3D/RBV Genotype 1a (F4) | 0.94 | 0.71 | 1.00 | Beta | (17) |
| 3D Genotype 1b | 0.99 | 0.74 | 1.00 | Beta | (16) |
| 3D Genotype 1b (F4) | 0.99 | 0.74 | 1.00 | Beta | (16, 57) |
| Treatment Disutilities | |||||
| Sofosbuvir/RBV | −0.04 | −0.05 | −0.03 | Beta | (26, 27) |
| Sofosbuvir/Interferon/RBV | −0.11 | −0.12 | −0.09 | Beta | (26, 27) |
| Sofosbuvir/Simeprevir | 0 | −0.04 | 0 | Beta | (53) |
| Drug Costs (weekly, ±25%) | |||||
| Interferon | $178 | $134 | $223 | Gamma | VA PBM |
| Ribavirin | $42 | $32 | $53 | Gamma | VA PBM |
| Simeprevir | $2,641 | $1,981 | $3,301 | Gamma | VA PBM |
| Sofosbuvir | $3,796 | $2,847 | $4,745 | Gamma | VA PBM |
| SOF/LDV | $3,440 | $500 | $7,875 | Gamma | (24) |
| 3D | $2,094 | $500 | $6,933 | Gamma | (24) |
| Medical Monitoring Costs (each, ±25%) | |||||
| Office visits | $76.19 | $57.14 | $95.24 | Gamma | (13, 25) |
| Complete blood count | $10.32 | $7.74 | $12.90 | Gamma | (13, 25) |
| Complete metabolic panel | $15.27 | $11.45 | $19.09 | Gamma | (13, 25) |
| Quantitative HCV PCR | $61.89 | $46.42 | $77.36 | Gamma | (13, 25) |
Note: HCV – hepatitis C, 3D – ombitasvir, ritonavir, paritaprevir, dasabuvir ± ribavirin, PCR – polymerase chain reaction test, SOF/LDV – sofosbuvir/ledipasvir, VA PBM - VA Pharmacy Benefits Management, RBV – ribavirin